FDA approves first typelir-23 monoanti-TREMFYA (guselkumab) for the treatment of psoriasis arthritis
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!----, The U.SFood and Drug Administration (FDA) has approved its TREMFYA (guselkumab) for the treatment of active psoriasis arthritis (PSA), characterized by joint pain and skin inflammationTREMFYA is the first typex (IL)-23 monotonica approved for the treatment of active PsA, which selectively binds to il-23's P19 sub-base and inhibits its interaction with IL-23 receptorsthe drug has been approved in the United States, Canada, the European Union and Japan for the treatment of adult patients with moderate to severe plaque psoriasishas been approved in the United States, Japan and Brazil for the treatment of adult patients with active psoriasisIL-23 is an important driver of the onset of inflammatory diseases such as psoriasis and psoriasis arthritisthe safety and efficacy of TREMFYA in PsA have been demonstrated in two key Phase 3 clinical trialsTREMFYA can be used alone or in combination with conventional anti-rheumatoid drugs or DMARDs such as methotrexatepsoriasis arthritis is a chronic, visor, immune-mediated disease characterized by arthritis, skin inflammation (inflammation of bones, tendons and ligaments), axial disease (pain) and skin lesions associated with psoriasisstudy shows that as many as 30 percent of the 8 million people with psoriasis in the United States have PsAthere is no cure for the disease, and despite the available treatments, most PsA patients are still looking for more options to help alleviate symptoms
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
